Lyudmila Boyanova is an expert in Infectiology at Medical University of Sofia (Bulgaria). Lyudmila Boyanova has authored 147 publications, the most recent in 2026, and is an investigator in 1 clinical trial. SLR score: 475 (community average: 125). How the SLR is computed.

LeadR Profile

Lyudmila Boyanova Medical University of Sofia Bulgaria
475 ScienceLeadR Reputation 475
Network Map

Infectiology

Subspecialties: Gastroenterology - Nutrition - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1996 - 2026

Source: PubMed

Medical University of Sofia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 147

Citations

Citations: 3 638 1st author: 80 Last author: 11 Unique author: 10


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
High In Vitro Activity of the Novel Pleuromutilin Antibiotic, Lefamulin, on Clinical Helicobacter pylori Isolates.
PMID 42650659 — levofloxacin, helicobacter pylori, clarithromycin, helicobacter
Antibiotics (Basel)20260
Genomic characterization of an unusual bloodstream Weissella viridescens isolate obtained from a Bulgarian intensive care unit patient.
PMID 42606628 — molecular biology, genome, probiotics, intensive care units, virulence, weissella
Mol Biol Rep20260
Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review.
PMID 42353704 — bacteria, anaerobic, vaginosis, bacterial, helicobacter pylori, helicobacter, periodontal diseases, research, therapeutics, bacteria, infections
Antibiotics (Basel)20260
Levofloxacin and Rifampin Resistance in Helicobacter pylori Isolates from Central-Western Colombia: Role of gyrA Mutations in Fluoroquinolone Resistance.
PMID 42192674 — levofloxacin, helicobacter pylori, helicobacter, fluoroquinolones, therapeutics, rifampin, mutation
Antibiotics (Basel)20260
Real-World Effectiveness and Safety of Saccharomyces boulardii CNCM I-745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp-EuReg).
PMID 41923280 — registries, helicobacter pylori, metronidazole, safety, incidence, clarithromycin, amoxicillin, helicobacter, saccharomyces boulardii, drug-related side effects and adverse reactions, saccharomyces, probiotics, therapeutics
Helicobacter20260

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1

By status:

Recruiting 1

By type:

Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map